Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304015 | 0.87 | PARP1 (0.55) | PARP1TSHRPOLBCYP3A4MAPT | |
| Benzamide SCHEMBL30112947 | 0.87 | PARP1 (1.00) | PARP1TSHRPOLBCYP3A4MAPT | |
| Benzamide SCHEMBL1332331 | 0.87 | — | — | |
| Benzamide SCHEMBL29618402 | 0.87 | — | — | |
| Benzamide SCHEMBL6690447 | 0.87 | PARP1 (1.00) | PARP1TSHRPOLBCYP3A4MAPT | |
| SCHEMBL67048 | 0.87 | — | — | |
| SCHEMBL21755166 | 0.87 | PARP1 (1.00) | PARP1TSHRPOLBCYP3A4MAPT | |
| Benzene SCHEMBL20971577 | 0.87 | BLM (0.52) | PARP1TSHRPOLBCYP3A4MAPT | |
| Benzamide SCHEMBL16352 | 0.87 | — | — | |
| Benzamide SCHEMBL1222101 | 0.87 | PARP1 (1.00) | PARP1TSHRPOLBCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-11633490-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3706736-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | The Regents of the University of Michigan (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | PARP1 1479/4885TSHR 3845/4885POLB 3508/4885 |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | ASH1L, ASH2L, DOT1L | PARP1 1479/4885TSHR 3845/4885POLB 3508/4885 |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | PARP1 1479/4885TSHR 3845/4885POLB 3508/4885 |
| US-11633490-B2 | — | ASH1L, ASH2L, STUB1 | PARP1 2319/4885TSHR 4070/4885POLB 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.